Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Venous Thrombosis

Free Subscription Articles published in Thromb Haemost Retrieve available abstracts of 122 articles: HTML format Text format

Single Articles

August 2018
1. KRAAIJPOEL N, Di Nisio M, Mulder FI, van Es N, et al
   Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
   Thromb Haemost. 2018;118:1439-1449.
   PubMed     Text format     Abstract available
   
   
   
2. JIMENEZ D, Bikdeli B
   Scores to Identify Occult Cancer in Venous Thromboembolism: Do They Work?
   Thromb Haemost. 2018;118:1343-1344.
   PubMed     Text format    
   
   
   July 2018
3. PETTERSON TM, Smith CY, Emerson JA, Bailey KR, et al
   Venous Thromboembolism (VTE) Incidence and VTE-Associated Survival among Olmsted County Residents of Local Nursing Homes.
   Thromb Haemost. 2018;118:1316-1328.
   PubMed     Text format     Abstract available
   
   
   June 2018
4. KRAAIJPOEL N, van Es N, Raskob GE, Buller HR, et al
   Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study.
   Thromb Haemost. 2018 Jun 4. doi: 10.1055/s-0038-1649523.
   PubMed     Text format     Abstract available
   
   
   April 2018
5. FRERE C, Trujillo-Santos J, Font C, Samperiz A, et al
   Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry.
   Thromb Haemost. 2018 Apr 21. doi: 10.1055/s-0038-1642009.
   PubMed     Text format    
   
   
   
6. BAUERSACHS R, Lee AYY, Kamphuisen PW, Meyer G, et al
   Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
   Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641150.
   PubMed     Text format     Abstract available
   
   
   
7. BOURGUIGNON T, Bernard A, Fauchier L
   Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis.
   Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641167.
   PubMed     Text format    
   
   
   
8. HUGON-RODIN J, Horellou MH, Conard J, Gompel A, et al
   Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
   Thromb Haemost. 2018 Apr 3. doi: 10.1055/s-0038-1641152.
   PubMed     Text format     Abstract available
   
   
   
9. GOLDMAN S, Fraczek P, Szklanny K, Papuga-Szela E, et al
   Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
   Thromb Haemost. 2018;118:654-663.
   PubMed     Text format     Abstract available
   
   
   March 2018
10. KHORANA AA, Weitz JI
    Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Thromb Haemost. 2018 Mar 22. doi: 10.1160/TH17-09-0681.
    PubMed     Text format     Abstract available
    
    
    
11. CAMM AJ
    The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Thromb Haemost. 2018 Mar 22. doi: 10.1055/s-0038-1632387.
    PubMed     Text format     Abstract available
    
    
    
12. BARBERO E, Bikdeli B, Chiluiza D, Barrios D, et al
    Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism.
    Thromb Haemost. 2018 Mar 19. doi: 10.1055/s-0038-1637746.
    PubMed     Text format    
    
    
    
13. LEHNERT P, Lange T, Moller CH, Olsen PS, et al
    Acute Pulmonary Embolism in a National Danish Cohort: Increasing Incidence and Decreasing Mortality.
    Thromb Haemost. 2018;118:539-546.
    PubMed     Text format     Abstract available
    
    
    February 2018
14. LUTSEY PL, Horvath KJ, Fullam L, Moll S, et al
    Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1625985.
    PubMed     Text format     Abstract available
    
    
    
15. MARTOS L, Ramon LA, Oto J, Fernandez-Pardo A, et al
    alpha2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:alpha2M Levels Are Associated with Venous Thromboembolism.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1629902.
    PubMed     Text format     Abstract available
    
    
    
16. VAN DER POL LM, van der Hulle T, Mairuhu ATA, Huisman MV, et al
    Combination of Pulmonary Embolism Rule-out Criteria and YEARS Algorithm in a European Cohort of Patients with Suspected Pulmonary Embolism.
    Thromb Haemost. 2018 Feb 1. doi: 10.1055/s-0038-1623535.
    PubMed     Text format     Abstract available
    
    
    
17. SPRONK HMH, Padro T, Siland JE, Prochaska JH, et al
    Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
    Thromb Haemost. 2018;118:229-250.
    PubMed     Text format     Abstract available
    
    
    January 2018
18. BIKDELI B, Jimenez D, Hawkins M, Ortiz S, et al
    Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE).
    Thromb Haemost. 2018;118:214-224.
    PubMed     Text format     Abstract available
    
    
    
19. BLONDON M, Spirk D, Kucher N, Aujesky D, et al
    Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients.
    Thromb Haemost. 2018;118:82-89.
    PubMed     Text format     Abstract available
    
    
    December 2017
20. KLOK FA, Ageno W, Barco S, Binder H, et al
    Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
    Thromb Haemost. 2017;117:2425-2434.
    PubMed     Text format    
    
    
    
21. MEDINA A, Raskob G, Ageno W, Cohen AT, et al
    Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Thromb Haemost. 2017;117:2406-2414.
    PubMed     Text format    
    
    
    
22. RAUZI F, Smyth E, Emerson M
    Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo.
    Thromb Haemost. 2017;117:2283-2290.
    PubMed     Text format    
    
    
    
23. BYKOV K, Bohn RL, Ewenstein BM, Seeger JD, et al
    Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
    Thromb Haemost. 2017;117:2267-2273.
    PubMed     Text format    
    
    
    
24. LEE LH, Gallus A, Jindal R, Wang C, et al
    Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review.
    Thromb Haemost. 2017;117:2243-2260.
    PubMed     Text format    
    
    
    November 2017
25. HALTON JML, Picard AC, Harper R, Huang F, et al
    Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Thromb Haemost. 2017;117:2168-2175.
    PubMed     Text format     Abstract available
    
    
    
26. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117:2163-2167.
    PubMed     Text format     Abstract available
    
    
    
27. KHORANA AA, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117:2135-2145.
    PubMed     Text format     Abstract available
    
    
    
28. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117:2045-2052.
    PubMed     Text format     Abstract available
    
    
    October 2017
29. BASS AR, Fields KG, Goto R, Turissini G, et al
    Clinical Decision Rules for Pulmonary Embolism in Hospitalized Patients: A Systematic Literature Review and Meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
30. VAN OMMEN CH, Klaassen ILM, van Els AL, van de Wetering MD, et al
    Increasing Incidence and Recurrence Rate of Venous Thromboembolism in Paediatric Oncology Patients in One Single Centre Over 25 Years.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
31. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
32. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    September 2017
33. KHORANA A, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
34. SCHULMAN S
    Accumulating data on rivaroxaban for venous thromboembolism in clinical practice.
    Thromb Haemost. 2017;117.
    PubMed     Text format    
    
    
    August 2017
35. SEILER E, Limacher A, Mean M, Beer HJ, et al
    Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
36. MCBANE RD, Loprinzi CL, Ashrani A, Perez-Botero J, et al
    Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
37. BLEKER SM, Brekelmans MPA, Eerenberg ES, Cohen AT, et al
    Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
38. ANETSBERGER A, Blobner M, Haller B, Schmid S, et al
    Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
39. TAKACH LAPNER S, Julian JA, Linkins LA, Bates S, et al
    Comparison of clinical probability-adjusted D-dimer and age-adjusted D-dimer interpretation to exclude venous thromboembolism.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
40. JANION-SADOWSKA A, Natorska J, Siudut J, Zabczyk M, et al
    Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    June 2017
41. COLEMAN CI, Coleman C, Bunz TJ, Turpie AGG, et al
    Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
42. SCHULMAN S, Ageno W, Konstantinides SV
    Venous thromboembolism: Past, present and future.
    Thromb Haemost. 2017;117:1219-1229.
    PubMed     Text format     Abstract available
    
    
    
43. VAN DER HULLE T, van Es N, den Exter P, van Es J, et al
    Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability? A patient-level meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    May 2017
44. CHUNG WS, Lin CL
    Increased risks of venous thromboembolism in patients with psoriasis. A Nationwide Cohort Study.
    Thromb Haemost. 2017 May 24. doi: 10.1160/TH17-01-0039.
    PubMed     Text format     Abstract available
    
    
    April 2017
45. SANTI RM, Ceccarelli M, Bernocco E, Monagheddu C, et al
    Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
    Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895.
    PubMed     Text format     Abstract available
    
    
    
46. SCHULMAN S, Singer D, Ageno W, Casella IB, et al
    NOACs for treatment of venous thromboembolism in clinical practice.
    Thromb Haemost. 2017 Apr 20. doi: 10.1160/TH17-01-0065.
    PubMed     Text format     Abstract available
    
    
    
47. COHEN AT, Gitt AK, Bauersachs R, Fronk EM, et al
    The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
    Thromb Haemost. 2017 Apr 13. doi: 10.1160/TH16-10-0793.
    PubMed     Text format     Abstract available
    
    
    March 2017
48. RAJPURKAR M, Biss T, Amankwah E, Martinez D, et al
    Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review.
    Thromb Haemost. 2017 Mar 23. doi: 10.1160/TH16-07-0529.
    PubMed     Text format     Abstract available
    
    
    
49. SINDET-PEDERSEN C, Langtved Pallisgaard J, Staerk L, Gerds TA, et al
    Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
    Thromb Haemost. 2017 Mar 16. doi: 10.1160/TH16-10-0745.
    PubMed     Text format     Abstract available
    
    
    
50. TAFUR AJ, Caprini JA, Cote L, Trujillo-Santos J, et al
    Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-11-0840.
    PubMed     Text format     Abstract available
    
    
    
51. KLOK FA, Barco S, Konstantinides SV
    External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-10-0810.
    PubMed     Text format     Abstract available
    
    
    February 2017
52. 
    Erratum to Heit et al. "Reasons for the persistent incidence of venous thromboembolism" (Thromb Haemost 2017; 117: 390-400).
    Thromb Haemost. 2017;117:643.
    PubMed     Text format    
    
    
    
53. DENTALI F, Mumoli N, Prisco D, Fontanella A, et al
    Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.
    Thromb Haemost. 2017;117:606-617.
    PubMed     Text format     Abstract available
    
    
    
54. DING Q, Yang L, Zhao X, Wu W, et al
    Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.
    Thromb Haemost. 2017;117:479-490.
    PubMed     Text format     Abstract available
    
    
    
55. HEIT JA, Armasu SM, McCauley BM, Kullo IJ, et al
    Identification of unique venous thromboembolism-susceptibility variants in African-Americans.
    Thromb Haemost. 2017 Feb 16. doi: 10.1160/TH16-08-0652.
    PubMed     Text format     Abstract available
    
    
    
56. BREKELMANS MP, Scheres LJ, Bleker SM, Hutten BA, et al
    Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Thromb Haemost. 2017 Feb 9. doi: 10.1160/TH16-11-0874.
    PubMed     Text format     Abstract available
    
    
    
57. STUCK AK, Spirk D, Schaudt J, Kucher N, et al
    Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-08-0631.
    PubMed     Text format     Abstract available
    
    
    
58. BOCHENEK ML, Rosinus NS, Lankeit M, Hobohm L, et al
    From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-10-0790.
    PubMed     Text format     Abstract available
    
    
    January 2017
59. CHAI-ADISAKSOPHA C, Linkins LA, ALKindi SY, Cheah M, et al
    Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
    Thromb Haemost. 2017 Jan 12. doi: 10.1160/TH16-09-0680.
    PubMed     Text format     Abstract available
    
    
    
60. ZHAO B, Zhang Y, Huang Y, Yu J, et al
    A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
    Thromb Haemost. 2017;117:44-56.
    PubMed     Text format     Abstract available
    
    
    December 2016
61. HEIT JA, Ashrani A, Crusan DJ, McBane RD, et al
    Reasons for the persistent incidence of venous thromboembolism.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    November 2016
62. CHATTERJEE S, Weinberg I, Yeh RW, Chakraborty A, et al
    Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    
63. AY C, Pabinger I, Cohen AT
    Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    
64. AGENO W, Casella I, Han CK, Raskob GE, et al
    RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    October 2016
65. TRUJILLO-SANTOS J, Di Micco P, Dentali F, Douketis J, et al
    Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    
66. RIEDL J, Kaider A, Marosi C, Prager GW, et al
    Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    
67. AMBROSINO P, Tarantino L, Di Minno G, Paternoster M, et al
    The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    
68. 
    Venous thromboembolism: A Call for risk assessment in all hospitalised patients.
    Thromb Haemost. 2016;116:777-779.
    PubMed     Text format    
    
    
    
69. COHEN AT, Katholing A, Rietbrock S, Bamber L, et al
    Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    September 2016
70. 
    Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
    Thromb Haemost. 2016;116:775.
    PubMed     Text format     Abstract available
    
    
    
71. WEITZ JI, Haas S, Ageno W, Angchaisuksiri P, et al
    Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
72. CAPPATO R, Welsh R
    Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
73. BLEKER SM, Cohen AT, Buller HR, Agnelli G, et al
    Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    August 2016
74. DI NISIO M, Vedovati MC, Riera-Mestre A, Prins MH, et al
    Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    July 2016
75. DELLUC A, Tromeur C, Le Ven F, Gouillou M, et al
    Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
76. VERHAMME P, Wells PS, Segers A, Ageno W, et al
    Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
77. ROLDAN V, Marin F
    Assessment of bleeding risk in acute ill medical patients. An essential part of venous thromboembolism prevention.
    Thromb Haemost. 2016;116.
    PubMed     Text format    
    
    
    
78. GOLDHABER SZ, Schellong S, Kakkar A, Eriksson H, et al
    Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
79. AMBROSINO P, Tarantino L, Criscuolo L, Nasto A, et al
    The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
80. NAGLER M, Kremer Hovinga JA, Alberio L, Peter-Salonen K, et al
    Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    June 2016
81. LUBBERTS B, Paulino Pereira NR, Kabrhel C, Kuter DJ, et al
    What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
82. KUCHER N, Aujesky D, Beer JH, Mazzolai L, et al
    Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
83. KITTELSON JM, Steg PG, Halperin JL, Goldenberg NA, et al
    Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
84. CROUS-BOU M, De Vivo I, Camargo CA Jr, Varraso R, et al
    Interactions of established risk factors and a GWAS-based genetic risk score on the risk of venous thromboembolism.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
85. AHMAD A, Sundquist K, Zoller B, Dahlback B, et al
    Identification of polymorphisms in Apolipoprotein M gene and their relationship with risk of recurrent venous thromboembolism.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
86. LARSEN TB, Skjoth F, Grove EL, Nielsen PB, et al
    Effectiveness of self-managed oral anticoagulant therapy in patients with recurrent venous thromboembolism. A propensity-matched cohort study.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    April 2016
87. MANCO-JOHNSON MJ, Bomgaars L, Palascak J, Shapiro A, et al
    Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    March 2016
88. BARCO S, Lankeit M, Binder H, Schellong S, et al
    Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
89. WANG MT, Liou JT, Huang YW, Lin CW, et al
    Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. A population-based nested case-control study.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available
    
    
    February 2016
90. PHILIPPART R, Brunet-Bernard A, Clementy N, Bourguignon T, et al
    Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available
    
    
    
91. WONG CC, Ng AC, Lau JK, Chow V, et al
    High mortality in patients presenting with acute pulmonary embolism and elevated INR not on anticoagulant therapy.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available
    
    
    January 2016
92. JIMENEZ D, Lobo JL, Fernandez-Golfin C, Portillo AK, et al
    Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available
    
    
    
93. POSCH F, Riedl J, Reitter EM, Kaider A, et al
    Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available
    
    
    December 2015
94. RASKOB GE, Gallus AS, Sanders P, Thompson JR, et al
    Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available
    
    
    
95. BRATEANU A, Patel K, Chagin K, Tunsupon P, et al
    Probability of developing proximal deep-vein thrombosis and/or pulmonary embolism after distal deep-vein thrombosis.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available
    
    
    
96. KONSTANTINIDES SV
    Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?
    Thromb Haemost. 2015;115.
    PubMed     Text format    
    
    
    November 2015
97. BARCO S, Woersching AL, Spyropoulos AC, Piovella F, et al
    European Union-28: An annualised cost-of-illness model for venous thromboembolism.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available
    
    
    
98. ANDRO M, Delluc A, Moineau MP, Tromeur C, et al
    Serum levels of 25(OH)D are not associated with venous thromboembolism in the elderly population. A case-control study.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available
    
    
    October 2015
99. DI NISIO M, Ageno W, Rutjes AW, Pap AF, et al
    Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available
    
    
    
100. ENGSTROM G, Zoller B, Svensson PJ, Melander O, et al
     Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
     Thromb Haemost. 2015;115.
     PubMed     Text format     Abstract available
     
     
     
101. LIU X, Thompson J, Phatak H, Mardekian J, et al
     Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial.
     Thromb Haemost. 2015;115.
     PubMed     Text format     Abstract available
     
     
     
102. CUNHA ML, Meijers JC, Middeldorp S
     Introduction to the analysis of next generation sequencing data and its application to venous thromboembolism.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     September 2015
103. MAJEED A, Goldhaber SZ, Kakkar A, Kearon C, et al
     Bleeding events with dabigatran or warfarin in patients with venous thromboembolism.
     Thromb Haemost. 2015;115.
     PubMed     Text format     Abstract available
     
     
     
104. DENTALI F, Ageno W, Pomero F, Fenoglio L, et al
     Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy.
     Thromb Haemost. 2015;115.
     PubMed     Text format     Abstract available
     
     
     
105. LIN JN, Chen HJ, Lin MC, Lai CH, et al
     Risk of venous thromboembolism in patients with splenic injury and splenectomy. A nationwide cohort study.
     Thromb Haemost. 2015;115.
     PubMed     Text format     Abstract available
     
     
     August 2015
106. IANOTTO JC, Chauveau A, Luque Paz D, Delluc A, et al
     Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism.
     Thromb Haemost. 2015;114.
     PubMed     Text format    
     
     
     
107. SUCHON P, Al Frouh F, Henneuse A, Ibrahim M, et al
     Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl Genetic Risk Monitoring (PILGRIM) Study.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
108. CHUNG WS, Lin CL, Kao CH
     Diabetesincreases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
109. VAN ES N, Di Nisio M, Bleker SM, Segers A, et al
     Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
110. ZOLLER B, Li X, Ohlsson H, Ji J, et al
     Family history of venous thromboembolism as a risk factor and genetic research tool.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
111. CUGNO M, Marzano AV, Bucciarelli P, Balice Y, et al
     Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     July 2015
112. KOOISTRA HA, Gebel M, Sahin K, Lensing AW, et al
     Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
113. TANG L, Hu Y
     Ethnic diversity in the genetics of venous thromboembolism.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     June 2015
114. BLACK SA, Cohen AT
     Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
115. HILLIS C, Crowther MA
     Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
     Thromb Haemost. 2015;113:1193-202.
     PubMed     Text format     Abstract available
     
     
     
116. GRANZIERA S, Cohen AT
     VTE primary prevention, including hospitalised medical and orthopaedic surgical patients.
     Thromb Haemost. 2015;113:1216-23.
     PubMed     Text format     Abstract available
     
     
     
117. PRANDONI P, Barbar S, Milan M, Campello E, et al
     Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
     Thromb Haemost. 2015;113:1210-5.
     PubMed     Text format     Abstract available
     
     
     May 2015
118. CHAI-ADISAKSOPHA C, Hillis C, Monreal M, Witt DM, et al
     Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
119. DEN EXTER PL, van Es J, Kroft LJ, Erkens PM, et al
     Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
120. LIPPI G, Mattiuzzi C, Franchini M
     Sleep apnea and venous thromboembolism. A systematic review.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
121. WEITZ JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al
     Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
     Thromb Haemost. 2015;114.
     PubMed     Text format     Abstract available
     
     
     
122. BASILI S, Proietti M, Perticone F, Corazza GR, et al
     Atrial fibrillation is not associated with increased risk of venous thromboembolism: Results from ARAPACIS study.
     Thromb Haemost. 2015;114.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Venous Thrombosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: